open access

Vol 26, No 5 (2021)
Research paper
Early publication date: 2021-08-13
Get Citation

Outcomes and computed tomography radiomic features extraction in soft tissue sarcomas treated with neoadjuvant radiation therapy

Javier González-Viguera1, Gabriel Reynés-Llompart2, Alicia Lozano1
DOI: 10.5603/RPOR.a2021.0092
·
Rep Pract Oncol Radiother 2021;26(5):804-813.
Affiliations
  1. Catalan Institute of Oncology, Radiation Oncology, L’Hospitalet de Llobregat, Spain
  2. Catalan Institute of Oncology, Medical Physics and Radiological Protection Service, L’Hospitalet de Llobregat, Spain

open access

Vol 26, No 5 (2021)
Original research articles
Early publication date: 2021-08-13

Abstract

Background: The aim of the study was to evaluate the management, toxicity and treatment responses of patients treated with neoadjuvant radiotherapy (NART) for soft tissue sarcomas (STS) and to analyse the potential of radiomic features extracted from computed tomography (CT) scans.

Materials and methods: This is a retrospective and exploratory study with patients treated between 2006 and 2019. Acute and chronic toxicities are evaluated. Local progression free survival (LPFS), distant progression free survival (DPFS) and overall survival (OS) are analysed. Radiomic features are obtained.

Results: A total of 25 patients were included. Median follow-up is 24 months. Complications in surgical wound healing were observed in 20% of patients, chronic fibrosis was documented as grade 1 (12%) and grade 2 (12%) without grade 3 events and chronic lymphedema as grade 1 (8%) and grade 2 (20%) without grade 3 events. Survival variables were LPFS 76%, DPFS 62% and OS 67.2% at 2-year follow-up. CT radiomics features were associated significantly with local control (GLCM-correlation), systemic control (HUmin, HUpeak, volume, GLCM-correlation and GLZLM-GLNU) and OS (GLZLM-SZE).

Conclusions: STS treated with NART in our centre associate with an OS and toxicity comparable to other series. CT radiomic features have a prognosis potential in STS risk stratification. The results of our study may serve as a motivation for future prospective studies with a greater number of patients.

Abstract

Background: The aim of the study was to evaluate the management, toxicity and treatment responses of patients treated with neoadjuvant radiotherapy (NART) for soft tissue sarcomas (STS) and to analyse the potential of radiomic features extracted from computed tomography (CT) scans.

Materials and methods: This is a retrospective and exploratory study with patients treated between 2006 and 2019. Acute and chronic toxicities are evaluated. Local progression free survival (LPFS), distant progression free survival (DPFS) and overall survival (OS) are analysed. Radiomic features are obtained.

Results: A total of 25 patients were included. Median follow-up is 24 months. Complications in surgical wound healing were observed in 20% of patients, chronic fibrosis was documented as grade 1 (12%) and grade 2 (12%) without grade 3 events and chronic lymphedema as grade 1 (8%) and grade 2 (20%) without grade 3 events. Survival variables were LPFS 76%, DPFS 62% and OS 67.2% at 2-year follow-up. CT radiomics features were associated significantly with local control (GLCM-correlation), systemic control (HUmin, HUpeak, volume, GLCM-correlation and GLZLM-GLNU) and OS (GLZLM-SZE).

Conclusions: STS treated with NART in our centre associate with an OS and toxicity comparable to other series. CT radiomic features have a prognosis potential in STS risk stratification. The results of our study may serve as a motivation for future prospective studies with a greater number of patients.

Get Citation

Keywords

soft tissue sarcomas; neoadjuvant radiotherapy; radiomic features

Supp./Additional Files (1)
Supplementary File
Download
155KB
About this article
Title

Outcomes and computed tomography radiomic features extraction in soft tissue sarcomas treated with neoadjuvant radiation therapy

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 26, No 5 (2021)

Article type

Research paper

Pages

804-813

Early publication date

2021-08-13

Page views

1812

Article views/downloads

152

DOI

10.5603/RPOR.a2021.0092

Bibliographic record

Rep Pract Oncol Radiother 2021;26(5):804-813.

Keywords

soft tissue sarcomas
neoadjuvant radiotherapy
radiomic features

Authors

Javier González-Viguera
Gabriel Reynés-Llompart
Alicia Lozano

References (17)
  1. Garcia del Muro X, de Alava E, Artigas V, et al. Spanish Group for Research on Sarcoma. Clinical practice guidelines for the diagnosis and treatment of patients with soft tissue sarcoma by the Spanish group for research in sarcomas (GEIS). Cancer Chemother Pharmacol. 2016; 77(1): 133–146.
  2. Burningham Z, Hashibe M, Spector L, et al. The epidemiology of sarcoma. Clin Sarcoma Res. 2012; 2(1): 14.
  3. Jo VY, Fletcher CDM. WHO classification of soft tissue tumours: an update based on the 2013 (4th) edition. Pathology. 2014; 46(2): 95–104.
  4. Rosenberg SA, Tepper J, Glatstein E, et al. The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg. 1982; 196(3): 305–315.
  5. O'Sullivan B, Davis AM, Turcotte R, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet. 2002; 359(9325): 2235–2241.
  6. Al-Absi E, Farrokhyar F, Sharma R, et al. A systematic review and meta-analysis of oncologic outcomes of pre- versus postoperative radiation in localized resectable soft-tissue sarcoma. Ann Surg Oncol. 2010; 17(5): 1367–1374.
  7. Sampath S, Schultheiss TE, Hitchcock YJ, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma: multi-institutional analysis of 821 patients. Int J Radiat Oncol Biol Phys. 2011; 81(2): 498–505.
  8. Alektiar KM, Brennan MF, Healey JH, et al. Impact of intensity-modulated radiation therapy on local control in primary soft-tissue sarcoma of the extremity. J Clin Oncol. 2008; 26(20): 3440–3444.
  9. Callegaro D, Miceli R, Mariani L, et al. Soft tissue sarcoma nomograms and their incorporation into practice. Cancer. 2017; 123(15): 2802–2820.
  10. Naghavi A, Yang G, Latifi K, et al. The Future of Radiation Oncology in Soft Tissue Sarcoma. Cancer Control. 2018; 25(1): 107327481881550.
  11. Tanaka K, Ozaki T. New TNM classification (AJCC eighth edition) of bone and soft tissue sarcomas: JCOG Bone and Soft Tissue Tumor Study Group. Jpn J Clin Oncol. 2019; 49(2): 103–107.
  12. Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Publish Date: November 27, 2017. . https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf.
  13. Nioche C, Orlhac F, Boughdad S, et al. LIFEx: A Freeware for Radiomic Feature Calculation in Multimodality Imaging to Accelerate Advances in the Characterization of Tumor Heterogeneity. Cancer Res. 2018; 78(16): 4786–4789.
  14. IBM Corp. IBM SPSS Statistics for Windows, Version 25.0. Released 2017.
  15. PyRadiomics Community. http://github.com/radiomics/pyradiomics.
  16. O'Sullivan B, Griffin AM, Dickie CI, et al. Phase 2 study of preoperative image-guided intensity-modulated radiation therapy to reduce wound and combined modality morbidities in lower extremity soft tissue sarcoma. Cancer. 2013; 119(10): 1878–1884.
  17. Peeken JC, Bernhofer M, Spraker MB, et al. CT-based radiomic features predict tumor grading and have prognostic value in patients with soft tissue sarcomas treated with neoadjuvant radiation therapy. Radiother Oncol. 2019; 135: 187–196.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl